Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the α-emitting radionuclide, bismuth 213

Blood

Volumn 100, Issue 1, 2002, Pages 208-216

  Zhang, Meili ^a,b,c   Yao, Zhengsheng ^a,b,c   Garmestani, Kayhan ^a,b,c   Axworthy, Donald B ^a,b,c   Zhang, Zhuo ^a,b,c   Mallett, Robert W ^a,b,c   Theodore, Louis J ^a,b,c   Goldman, Carolyn K ^a,b,c   Brechbiel, Martin W ^a,b,c   Carrasquillo, Jorge A ^a,b,c   Waldmann, Thomas A ^a,b,c,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CLINICAL CENTER   (United States)

^c Poniard Pharmaceuticals Inc   (United States)

^d CCR   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID BIOTIN BI 213; ACTINIUM; ANTIBODY CONJUGATE; BETA 2 MICROGLOBULIN; BISMUTH 213; HUMANIZED TAC ANTIBODY STREPTAVIDIN; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; INTERLEUKIN 2 RECEPTOR ANTIBODY STREPTAVIDIN; IODINE 125; STREPTAVIDIN; UNCLASSIFIED DRUG; YTTRIUM 90;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONJUGATION; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RECEPTOR BINDING; SURVIVAL RATE; T CELL LEUKEMIA; TREATMENT OUTCOME;

EID: 0036659932     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-01-0107     Document Type: Article

References (42)

1. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: a report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79:428-437.
2. Uchiyama T, Broder S, Waldmann TA. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells, I: production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol. 1981;126:1393-1397.
3. Uchiyama T, Hori T, Tsudo M, et al. Interleukin-2 receptor (Tac antigen) expressed on adult T cell leukemia cells. J Clin Invest. 1985;76:446-453.
4. Waldmann TA, Greene WC, Sarin PS, et al. Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative Sezary leukemia, and their distinction using anti-Tac: monoclonal antibody identifying the human receptor for T cell growth factor. J Clin Invest. 1984;73:1711-1718.
5. Waldmann TA, White JD, Carrasquillo JA, et al. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood. 1995;86:4063-4075.
6. Phillips KE, Herdng B, Wilson LA, et al. IL-2Ralpha-directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction. Cancer Res. 2000;60:6977-6984.
7. Carrasquillo JA, Bunn PA Jr, Keenan AM, et al. Radioimmunodetection of cutaneous T-cell lymphoma with 111In-labeled T101 monoclonal antibody. N Engl J Med. 1986;315:673-680.
8. DeNardo GL, Lamborn KR, Goldstein DS, Kroger LA, DeNardo SJ. Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Cancer. 1997;80:2706-2711.
9. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 1996;14:1974-1981.
10. Cassidy J, Newell DR, Wedge SR, Cummings J. Pharmacokinetics of high molecular weight agents. Cancer Surv. 1993;17:315-341.
11. Knox SJ. Overview of studies on experimental radioimmunotherapy. Cancer Res. 1995;55: 5832s-5836s.
12. Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med. 1987;28:1294-1302.
13. Yao Z, Zhang M, Kobayashi H, et al. Improved targeting of radiolabeled streptavidin in tumors pretargeted with biotinylated monoclonal antibodies through an avidin chase. J Nucl Med. 1995; 36:837-841.
14. Zhang M, Yao Z, Saga T, et al. Improved intratumoral penetration of radiolabeled streptavidin in intraperitoneal tumors pretargeted with biotinylated antibody. J Nucl Med. 1998;39:30-33.
15. Goodwin DA. New methods for localizing infection: a role for avidin-biotin? J Nucl Med. 1992;33:1816-1818.
16. Paganelli G, Magnani P, Zito F, et al. Three-step monoclonal antibody tumor targeting in carcino-embryonic antigen-positive patients. Cancer Res. 1991;51:5960-5966.
17. Kafofonos HP, Rusckowski M, Siebecker DA, et al. Imaging of tumor in patients with indium-111labeled biotin and streptavidin-conjugated antibodies: preliminary communication. J Nucl Med. 1990;31:1791-1796.
18. Green NM. Avidin and streptavidin. Methods Enzymol. 1990;184:51-67.
19. Axworthy DB, Reno JM, Hylarides MD, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci U S A. 2000;97:1802-1807.
20. Knox SJ, Goris ML, Tempero M, et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res. 2000;6:406-414.
21. Breitz HB, Weiden PL, Beaumier PL, et al. Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin. J Nucl Med. 2000;41:131-140.
22. Weiden PL, Breitz HB, Press O, et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. Cancer Biother Radiopharm. 2000;15:15-29.
23. Schultz J, Lin Y, Sanderson J, et al. A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. Cancer Res. 2000;60:6663-6669.
24. McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science. 2001;294:1537-1540.
25. Macklis RM, Kinsey BM, Kassis AI, et al. Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Science. 1988;240:1024-1026.
26. McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med. 1998;25:1341-1351.
27. Macklis RM, Kaplan WD, Ferrara JL, et al. Alpha particle radio-immunotherapy: animal models and clinical prospects. Int J Radiat Oncol Biol Phys. 1989;16:1377-1387.
28. Hartmann F, Horak EM, Garmestani K, et al. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac. Cancer Res. 1994;54:4362-4370.
29. Horak E, Hartmann F, Garmestani K, et al. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1. J Nucl Med. 1997;38:1944-1950.
30. Queen C, Schneider WP, Selick HE, et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A. 1989;86: 10029-10033.
31. Mirzadeh S, Brechbiel MW, Archer RW, Gansow OA. Radiometal labeling of immunoproteins: covalent linkage of 2-(4-isothiocyanatobenzyl)diethylenetriaminepentaacetic acid ligands to immunoglobulin. Bioconjug Chem. 1990;1:59-65.
32. Pastan I, Lovelace ET, Gallo MG, Rutherford AV, Magnani JL, Willingham MC. Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas. Cancer Res. 1991;51:3781-3787.
33. Pippin CG, Gansow OA, Brechbiel MW, et al. Recovery of Bi-213 from an Ac-225 cow: application of the radiolabeling of antibodies with Bi-213. In: Emran AM, ed. Chemists' Views of Imaging Centers. New York, NY: Plenum Press; 1995:315-322.
34. Garmestani K, Yao Z, Zhang M, et al. Synthesis and evaluation of a macrocyclic bifunctional chelating agent for use with bismuth radionuclides. Nucl Med Biol. 2001;28:409-418.
35. Yao Z, Sakahara H, Zhang M, et al. Radioimmunoimaging of colon cancer xenografts with anti-Tn monoclonal antibody. Nucl Med Biol. 1995;22:199-203.
36. Yao Z, Garmestani K, Wong KJ, et al. Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody. J Nucl Med. 2001;42:1538-1544.
37. Waldmann TA, White JD, Goldman CK, et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood. 1993;82:1701-1712.
38. Waldmann TA, Pastan IH, Gansow OA, Junghans RP. The multichain interleukin-2 receptor: a target for immunotherapy. Ann Intern Med. 1992;116:148-160.
39. Le Doussal JM, Barbet J, Delaage M. Bispecific-antibody-mediated targeting of radiolabeled bivalent haptens: theoretical, experimental and clinical results. Int J Cancer Suppl. 1992;7:58-62.
40. Barbet J, Peltier P, Bardet S, et al. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody. J Nucl Med. 1998;39:1172-1178.
41. Yao Z, Zhang M, Wong KJ, et al. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody/streptavidin and Y-90-biotin [abstract]. J Nucl Med. 2001;42:152.
42. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 1998:58:2825-2831.